Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan M Alonso

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
BMC Public Health|November 27, 2012
A cluster-randomised clinical trial comparing two cardiovascular health education strategies in a child population: the Savinghearts projectLuis María Sánchez-Gómez, María Jesús Fernández-Luque, Lourdes Ruiz-Díaz, et al.
Cancer|June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Scientific Reports|October 21, 2021
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Juan M Alonso-Dominguez, Eva Barragán, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Cancer|April 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registryJuan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.
Leukemia Research|December 24, 2025
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratoriesMargarida Coucelo, Claudia Sargas, Rosa Ayala, et al.
Haematologica|November 12, 2020
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Rosa Ayala, María Carmen Chillón, et al.
Cancers|March 13, 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Rebeca Rodriguez-Veiga, Claudia Sargas, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
BMC Public Health|November 27, 2012
A cluster-randomised clinical trial comparing two cardiovascular health education strategies in a child population: the Savinghearts projectLuis María Sánchez-Gómez, María Jesús Fernández-Luque, Lourdes Ruiz-Díaz, et al.
Cancer|June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Scientific Reports|October 21, 2021
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Juan M Alonso-Dominguez, Eva Barragán, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Cancer|April 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registryJuan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.
Leukemia Research|December 24, 2025
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratoriesMargarida Coucelo, Claudia Sargas, Rosa Ayala, et al.
Haematologica|November 12, 2020
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Rosa Ayala, María Carmen Chillón, et al.
Cancers|March 13, 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Rebeca Rodriguez-Veiga, Claudia Sargas, et al.
Pageof 4